Takara Bio Inc operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Takara Bio Inc with three other
companies in this sector in Japan:
Linical Company Limited
sales of 11.31 billion Japanese Yen [US$103.74 million]
of which 92%
was Cro Business),
Shin Nippon Biomedical Laboratories Ltd
(15.66 billion Japanese Yen [US$143.59 million]
of which 88%
was Pre-Clinical Business), and
Morishita Jintan Co., Ltd.
(10.09 billion Japanese Yen [US$92.53 million]
of which 74%
was Health Care Business).
Takara Bio Inc reported sales of ¥35.84 billion (US$328.66 million)
March of 2019.
increase of 10.9%
versus 2018, when the company's sales were ¥32.31 billion.
Sales of Gene Medical Care saw an increase
that was more than double the company's growth rate: sales were up
388.6% in 2019, from
¥500.00 million to ¥2.44 billion.
Not all segments of Takara Bio Inc experienced an increase in sales in 2019:
sales of Food and Bio Medical fell 18.8% to ¥1.82 billion.